Next Article in Journal
Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation
Previous Article in Journal
Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003–2006 with 2010–2011
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 24
Issue 6
10.3747/co.24.3335
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ovarian Function after Chemotherapy in Young Breast Cancer Survivors

by
K. Morarji
1,
O. McArdle
1,
K. Hui
1,
G. Gingras-Hill
1,
S. Ahmed
1,
E. M. Greenblatt
2,3,
E. Warner
4,
S. Sridhar
5,
A. M. F. Ali
4,
A. Azad
6 and
D. C. Hodgson
1,*
1
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada
2
Department of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, ON, Canada
3
University of Toronto, Toronto, ON, Canada
4
Department of Medical Oncology, Odette Cancer Centre, Toronto, ON, Canada
5
Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada
6
Pathology and Laboratory Medicine Unit, Mount Sinai Hospital, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(6), 494-502; https://doi.org/10.3747/co.24.3335
Submission received: 4 September 2017 / Revised: 3 October 2017 / Accepted: 6 November 2017 / Published: 1 December 2017

Abstract

Background: As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment—and impaired fertility in particular—are emerging as important concerns among young breast cancer survivors. Older reports have evaluated the occurrence of amenorrhea after treatment, but few data have been reported about the incidence of biochemical evidence for impaired ovarian function in patients who do not become overtly menopausal. Methods: We conducted a cross-sectional study evaluating anti-Müllerian hormone (AMH) in premenopausal chemotherapy-treated breast cancer survivors and control patients. Random serum levels of AMH and other relevant clinical data were collected for 100 premenopausal chemotherapy-treated breast cancer survivors and 76 control subjects. Subgroup analyses were performed for women with regular menstrual cycles at the time of AMH testing. Results: After adjustment for age, AMH was significantly lower in the overall group of patients receiving chemotherapy (p = 0.002) and in the subgroup reporting normal cycles (p = 0.03). Cyclophosphamide produced a significant dose-dependent reduction in AMH (p < 0.001); trastuzumab was associated with increased AMH in survivors with normal cycles. Overall, serum AMH in survivors was roughly equivalent to that measured in control patients 12 years older. Conclusions: Young breast cancer survivors often experience significant impairment of ovarian function despite having normal menstrual cycles after treatment. Those results have important implications for patient counselling and the timing of possible referral to a fertility specialist.
Keywords: anti-Müllerian hormone; breast cancer survivors; ovarian reserve; chemotherapy anti-Müllerian hormone; breast cancer survivors; ovarian reserve; chemotherapy

Share and Cite

MDPI and ACS Style

Morarji, K.; McArdle, O.; Hui, K.; Gingras-Hill, G.; Ahmed, S.; Greenblatt, E.M.; Warner, E.; Sridhar, S.; Ali, A.M.F.; Azad, A.; et al. Ovarian Function after Chemotherapy in Young Breast Cancer Survivors. Curr. Oncol. 2017, 24, 494-502. https://doi.org/10.3747/co.24.3335

AMA Style

Morarji K, McArdle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, Warner E, Sridhar S, Ali AMF, Azad A, et al. Ovarian Function after Chemotherapy in Young Breast Cancer Survivors. Current Oncology. 2017; 24(6):494-502. https://doi.org/10.3747/co.24.3335

Chicago/Turabian Style

Morarji, K., O. McArdle, K. Hui, G. Gingras-Hill, S. Ahmed, E. M. Greenblatt, E. Warner, S. Sridhar, A. M. F. Ali, A. Azad, and et al. 2017. "Ovarian Function after Chemotherapy in Young Breast Cancer Survivors" Current Oncology 24, no. 6: 494-502. https://doi.org/10.3747/co.24.3335

APA Style

Morarji, K., McArdle, O., Hui, K., Gingras-Hill, G., Ahmed, S., Greenblatt, E. M., Warner, E., Sridhar, S., Ali, A. M. F., Azad, A., & Hodgson, D. C. (2017). Ovarian Function after Chemotherapy in Young Breast Cancer Survivors. Current Oncology, 24(6), 494-502. https://doi.org/10.3747/co.24.3335

Article Metrics

Back to TopTop